JP5149478B2 - プロミオスタチンペプチドおよびその使用法 - Google Patents

プロミオスタチンペプチドおよびその使用法 Download PDF

Info

Publication number
JP5149478B2
JP5149478B2 JP2002515196A JP2002515196A JP5149478B2 JP 5149478 B2 JP5149478 B2 JP 5149478B2 JP 2002515196 A JP2002515196 A JP 2002515196A JP 2002515196 A JP2002515196 A JP 2002515196A JP 5149478 B2 JP5149478 B2 JP 5149478B2
Authority
JP
Japan
Prior art keywords
myostatin
gdf
receptor
peptide
mice
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2002515196A
Other languages
English (en)
Japanese (ja)
Other versions
JP2004504826A (ja
JP2004504826A5 (cg-RX-API-DMAC7.html
Inventor
セ−ジン リー
アレクサンドラ シー． マックフェロン
Original Assignee
ザ ジョーンズ ホプキンス ユニバーシティー スクール オブ メディシン
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US09/628,112 external-priority patent/US7566768B1/en
Application filed by ザ ジョーンズ ホプキンス ユニバーシティー スクール オブ メディシン filed Critical ザ ジョーンズ ホプキンス ユニバーシティー スクール オブ メディシン
Publication of JP2004504826A publication Critical patent/JP2004504826A/ja
Publication of JP2004504826A5 publication Critical patent/JP2004504826A5/ja
Application granted granted Critical
Publication of JP5149478B2 publication Critical patent/JP5149478B2/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • C07K5/1019—Tetrapeptides with the first amino acid being basic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Veterinary Medicine (AREA)
  • Neurology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
JP2002515196A 2000-07-27 2001-07-26 プロミオスタチンペプチドおよびその使用法 Expired - Fee Related JP5149478B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US09/628,112 US7566768B1 (en) 1995-10-26 2000-07-27 Promyostatin peptides and methods of using same
US09/628,112 2000-07-27
PCT/US2001/023510 WO2002009641A2 (en) 2000-07-27 2001-07-26 Promyostatin peptides and methods of using same

Publications (3)

Publication Number Publication Date
JP2004504826A JP2004504826A (ja) 2004-02-19
JP2004504826A5 JP2004504826A5 (cg-RX-API-DMAC7.html) 2008-09-11
JP5149478B2 true JP5149478B2 (ja) 2013-02-20

Family

ID=24517522

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2002515196A Expired - Fee Related JP5149478B2 (ja) 2000-07-27 2001-07-26 プロミオスタチンペプチドおよびその使用法

Country Status (14)

Country Link
US (3) US7393682B1 (cg-RX-API-DMAC7.html)
EP (2) EP2360259A3 (cg-RX-API-DMAC7.html)
JP (1) JP5149478B2 (cg-RX-API-DMAC7.html)
CN (2) CN101261277B (cg-RX-API-DMAC7.html)
AR (1) AR030307A1 (cg-RX-API-DMAC7.html)
AU (2) AU8079901A (cg-RX-API-DMAC7.html)
BR (1) BRPI0112785B1 (cg-RX-API-DMAC7.html)
CA (1) CA2416260A1 (cg-RX-API-DMAC7.html)
IL (2) IL153970A0 (cg-RX-API-DMAC7.html)
MX (1) MXPA03000786A (cg-RX-API-DMAC7.html)
NZ (2) NZ523672A (cg-RX-API-DMAC7.html)
PL (1) PL210158B1 (cg-RX-API-DMAC7.html)
WO (1) WO2002009641A2 (cg-RX-API-DMAC7.html)
ZA (1) ZA200300483B (cg-RX-API-DMAC7.html)

Families Citing this family (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7393682B1 (en) * 1993-03-19 2008-07-01 The Johns Hopkins University School Of Medicine Polynucleotides encoding promyostatin polypeptides
US7566768B1 (en) 1995-10-26 2009-07-28 The Johns Hopkins University School Of Medicine Promyostatin peptides and methods of using same
TWI329129B (en) 2001-02-08 2010-08-21 Wyeth Corp Modified and stabilized gdf propeptides and uses thereof
US7320789B2 (en) 2001-09-26 2008-01-22 Wyeth Antibody inhibitors of GDF-8 and uses thereof
PL374966A1 (en) 2002-02-21 2005-11-14 Wyeth Follistatin domain containing proteins
IL163525A0 (en) 2002-02-21 2005-12-18 Wyeth Corp A follistatin domain containing protein
ATE461275T1 (de) * 2002-09-16 2010-04-15 Univ Johns Hopkins Metalloproteaseaktivierung von myostatin und verfahren zur modulation der myostatinaktivität
US7261893B2 (en) 2002-10-22 2007-08-28 Wyeth Neutralizing antibodies against GDF-8 and uses therefor
US20040223966A1 (en) * 2002-10-25 2004-11-11 Wolfman Neil M. ActRIIB fusion polypeptides and uses therefor
AR042545A1 (es) * 2002-12-20 2005-06-22 Amgen Inc Agentes ligantes que inhiben la miostatina
AU2013216655B2 (en) * 2002-12-20 2016-05-26 Amgen Inc. Binding agents which inhibit myostatin
US9068234B2 (en) * 2003-01-21 2015-06-30 Ptc Therapeutics, Inc. Methods and agents for screening for compounds capable of modulating gene expression
MXPA05012965A (es) * 2003-06-02 2006-03-09 Wyeth Corp Uso de inhibidores de miostatina (gdf8) en conjuncion con corticoesteroides para el tratamiento de desordenes neuromusculares y composiciones farmaceuticas para ello.
ATE552272T1 (de) * 2004-09-30 2012-04-15 Orico Ltd Myostatin-isoform
BRPI0609449A2 (pt) * 2005-03-23 2010-04-06 Wyeth Corp detecção de agentes de modulação de gdf-8
MX2008002367A (es) 2005-08-19 2008-03-18 Wyeth Corp Anticuerpos antagonistas contra el factor 8 de crecimiento y diferenciacion y usos en el tratamiento de esclerosis lateral amiotrofica y otros trastornos relacionados con el factor 8 de crecimiento y diferenciacion.
US7635760B2 (en) 2005-10-06 2009-12-22 Eli Lilly And Company Anti-myostatin antibodies
UA92504C2 (en) 2005-10-12 2010-11-10 Эли Лилли Энд Компани Anti-myostatin monoclonal antibody
US20070149458A1 (en) * 2005-12-06 2007-06-28 Amgen Inc. Uses of myostatin antagonists
CA2647846C (en) 2006-03-31 2016-06-21 Chugai Seiyaku Kabushiki Kaisha Methods for controlling blood pharmacokinetics of antibodies
EP2054434B1 (en) 2006-08-03 2017-03-15 Myostin Therapeutics Pty Ltd Myostatin antagonists
UA98308C2 (en) * 2006-09-05 2012-05-10 Эли Лилли Энд Компани Anti-myostatin antibody
PL2202245T3 (pl) 2007-09-26 2017-02-28 Chugai Seiyaku Kabushiki Kaisha Sposób modyfikowania punktu izoelektrycznego przeciwciała poprzez podstawienie aminokwasu w cdr
KR102269708B1 (ko) 2008-04-11 2021-06-25 추가이 세이야쿠 가부시키가이샤 복수 분자의 항원에 반복 결합하는 항원 결합 분자
JP2012021973A (ja) * 2010-06-15 2012-02-02 Nitto Denko Corp Ｓｐｒセンサセルおよびｓｐｒセンサ
EP4231014A3 (en) 2010-11-30 2024-08-14 Chugai Seiyaku Kabushiki Kaisha Antigen-binding molecule capable of binding to plurality of antigen molecules repeatedly
NZ702269A (en) 2012-06-15 2017-07-28 Pfizer Improved antagonist antibodies against gdf-8 and uses therefor
SG10201709559PA (en) 2012-08-24 2017-12-28 Chugai Pharmaceutical Co Ltd Fcγriib-specific fc region variant
EP2889376A4 (en) 2012-08-24 2016-11-02 Chugai Pharmaceutical Co Ltd ANTIBODIES Fc SPECIFIC TO FCTRII OF MOUSE
SG11201501741YA (en) 2012-09-13 2015-04-29 Bristol Myers Squibb Co Fibronectin based scaffold domain proteins that bind to myostatin
CN105246914B (zh) 2013-04-02 2021-08-27 中外制药株式会社 Fc区变体
WO2014168973A2 (en) 2013-04-08 2014-10-16 President And Fellows Of Harvard College Methods and compositions for rejuvenating skeletal muscle stem cells
SG10201800800YA (en) 2013-05-06 2018-03-28 Scholar Rock Inc Compositions and methods for growth factor modulation
US20160220640A1 (en) 2013-06-11 2016-08-04 The Brigham And Women's Hospital, Inc. Methods and compositions for increasing neurogenesis and angiogenesis
WO2016073879A2 (en) * 2014-11-06 2016-05-12 Scholar Rock, Inc. Transforming growth factor-related antibodies and uses thereof
EP3215175A4 (en) * 2014-11-06 2018-06-27 Scholar Rock, Inc. Anti-pro/latent-myostatin antibodies and uses thereof
IL278014B2 (en) 2014-12-19 2023-10-01 Chugai Pharmaceutical Co Ltd Anti-myostatin antibodies, polypeptides containing variable FC regions and methods of use
CN107108729A (zh) 2015-02-05 2017-08-29 中外制药株式会社 包含离子浓度依赖性的抗原结合结构域的抗体，fc区变体，il‑8‑结合抗体，及其应用
ES3030258T3 (en) 2015-09-15 2025-06-27 Scholar Rock Inc Anti-pro/latent-myostatin antibodies and uses thereof
EP3394098A4 (en) 2015-12-25 2019-11-13 Chugai Seiyaku Kabushiki Kaisha ANTI-MYOSTATIN ANTIBODIES AND METHODS OF USE
EP3949979A1 (en) 2016-01-06 2022-02-09 President and Fellows of Harvard College Treatment with gdf11 prevents weight gain, improves glucose tolerance and reduces hepatosteatosis
JP2019504064A (ja) 2016-01-08 2019-02-14 スカラー ロック インコーポレイテッドＳｃｈｏｌａｒ Ｒｏｃｋ，Ｉｎｃ． 抗プロ／潜在型ミオスタチン抗体およびその使用方法
KR102271635B1 (ko) 2016-06-13 2021-07-06 스칼러 락, 인크. 미오스타틴 억제제의 용도 및 조합 요법
TWI831965B (zh) 2016-08-05 2024-02-11 日商中外製藥股份有限公司 Il-8相關疾病之治療用或預防用組成物
HUE061656T2 (hu) 2017-01-06 2023-07-28 Scholar Rock Inc Metabolikus betegségek kezelése a miosztatin aktiválás gátlásával
CN111793123B (zh) * 2019-04-08 2022-03-08 中国农业大学 一种肌肉生长抑制素mstn的突变体及其应用
CN110192624A (zh) * 2019-07-05 2019-09-03 福建冠丰生物科技有限公司 一种海参牡蛎营养物口服含片及其制备方法
EP3839051A1 (en) * 2019-12-19 2021-06-23 Evonik Operations GmbH Method for the fermentative production of guanidinoacetic acid
CA3184852A1 (en) 2020-07-10 2022-01-13 Lida Katsimpardi Use of gdf11 to diagnose and treat anxiety and depression
WO2024107652A1 (en) * 2022-11-14 2024-05-23 John Mansell Myostatin inhibition
AU2023413166A1 (en) 2022-12-22 2025-07-03 Scholar Rock, Inc. Selective and potent inhibitory antibodies of myostatin activation

Family Cites Families (56)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US732575A (en) * 1902-10-04 1903-06-30 Louis G Mayer Carriage-spring.
US4036945A (en) 1976-05-03 1977-07-19 The Massachusetts General Hospital Composition and method for determining the size and location of myocardial infarcts
US4331647A (en) 1980-03-03 1982-05-25 Goldenberg Milton David Tumor localization and therapy with labeled antibody fragments specific to tumor-associated markers
US4873191A (en) 1981-06-12 1989-10-10 Ohio University Genetic transformation of zygotes
US4766073A (en) * 1985-02-25 1988-08-23 Zymogenetics Inc. Expression of biologically active PDGF analogs in eucaryotic cells
US5206347A (en) 1985-08-06 1993-04-27 La Jolla Cancer Research Foundation Isolation and use of receptors binding to a peptide column
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
US5011912A (en) 1986-12-19 1991-04-30 Immunex Corporation Hybridoma and monoclonal antibody for use in an immunoaffinity purification system
US5162215A (en) 1988-09-22 1992-11-10 Amgen Inc. Method of gene transfer into chickens and other avian species
US5399346A (en) 1989-06-14 1995-03-21 The United States Of America As Represented By The Department Of Health And Human Services Gene therapy
US5350836A (en) * 1989-10-12 1994-09-27 Ohio University Growth hormone antagonists
US5225212A (en) 1989-10-20 1993-07-06 Liposome Technology, Inc. Microreservoir liposome composition and method
JPH05503003A (ja) 1989-11-22 1993-05-27 ジェネンテク，インコーポレイテッド 潜在性関与ペプチドおよびその使用
US5283173A (en) 1990-01-24 1994-02-01 The Research Foundation Of State University Of New York System to detect protein-protein interactions
ATE149841T1 (de) 1990-01-26 1997-03-15 Immunomedics Inc Impfstoffe gegen krebs und infektionskrankheiten
AU7312891A (en) 1990-02-12 1991-09-03 Board Of Regents, The University Of Texas System Satellite cell proliferation in adult skeletal muscle
US5265030A (en) 1990-04-24 1993-11-23 Scripps Clinic And Research Foundation System and method for determining three-dimensional structures of proteins
US5750342A (en) 1990-06-11 1998-05-12 Nexstar Pharmaceuticals, Inc. Nucleic acid ligands of tissue target
US5264563A (en) 1990-08-24 1993-11-23 Ixsys Inc. Process for synthesizing oligonucleotides with random codons
US5314695A (en) 1990-11-13 1994-05-24 Corvas International, Inc. Tissue factor based prothrombin time reagent
US5885794A (en) 1991-05-10 1999-03-23 The Salk Institute For Biological Studies Recombinant production of vertebrate activin receptor polypeptides and identification of receptor DNAs in the activin/TGF-β superfamily
AU2408292A (en) 1991-07-11 1993-02-11 Regents Of The University Of California, The A method to identify protein sequences that fold into a known three-dimensional structure
US5585479A (en) * 1992-07-24 1996-12-17 The United States Of America As Represented By The Secretary Of The Navy Antisense oligonucleotides directed against human ELAM-I RNA
JP3415643B2 (ja) * 1992-12-04 2003-06-09 株式会社ミノファーゲン製薬 筋ジストロフィー症治療薬
US5395619A (en) 1993-03-03 1995-03-07 Liposome Technology, Inc. Lipid-polymer conjugates and liposomes
US5994618A (en) * 1997-02-05 1999-11-30 Johns Hopkins University School Of Medicine Growth differentiation factor-8 transgenic mice
US20030074680A1 (en) * 1993-03-19 2003-04-17 Johns Hopkins University School Of Medicine Growth differentiation factor-8
US6465239B1 (en) * 1993-03-19 2002-10-15 The John Hopkins University School Of Medicine Growth differentiation factor-8 nucleic acid and polypeptides from aquatic species and non-human transgenic aquatic species
US6607884B1 (en) * 1993-03-19 2003-08-19 The Johns Hopkins University School Of Medicine Methods of detecting growth differentiation factor-8
US7393682B1 (en) * 1993-03-19 2008-07-01 The Johns Hopkins University School Of Medicine Polynucleotides encoding promyostatin polypeptides
EP1333035A3 (en) 1993-03-19 2004-07-07 The Johns Hopkins University School Of Medicine Growth differentiation factor-8
KR100227406B1 (ko) * 1993-05-12 1999-12-01 브루스 엠. 에이센 Bmp-11 조성물
US7332575B2 (en) * 1994-03-18 2008-02-19 The Johns Hopkins University School Of Medicine Growth differentiation factor-8 nucleic acid and polypeptide from aquatic species, and transgenic aquatic species
DK0776337T3 (da) 1994-07-08 2005-12-12 Univ Johns Hopkins Med Vækstdifferentieringsfaktor-11
US5616561A (en) 1995-03-31 1997-04-01 Regents Of The University Of California TGF-β antagonists as mitigators of radiation-induced tissue damage
CN1151269C (zh) * 1995-06-06 2004-05-26 扬·维吉 用于诊断性dna检测的方法
US5622699A (en) 1995-09-11 1997-04-22 La Jolla Cancer Research Foundation Method of identifying molecules that home to a selected organ in vivo
DE19626982C1 (de) 1996-07-04 1997-09-25 Siemens Ag Elektromagnetisches Relais und Verfahren zu dessen Herstellung
US5776689A (en) 1996-07-19 1998-07-07 The Regents Of The University Of California Protein recruitment system
WO1998033887A1 (en) 1997-02-05 1998-08-06 The Johns Hopkins University School Of Medicine Growth differentiation factor-8
US5827533A (en) 1997-02-06 1998-10-27 Duke University Liposomes containing active agents aggregated with lipid surfactants
US5933819C1 (en) 1997-05-23 2001-11-13 Scripps Research Inst Prediction of relative binding motifs of biologically active peptides and peptide mimetics
US6103466A (en) * 1997-07-14 2000-08-15 University Of Liege Double-muscling in mammals
DK2045322T3 (en) 1997-07-14 2015-10-05 Université de Liège DOUBLE MUSCULAR FOR MAMMALS
US6656475B1 (en) * 1997-08-01 2003-12-02 The Johns Hopkins University School Of Medicine Growth differentiation factor receptors, agonists and antagonists thereof, and methods of using same
US6696260B1 (en) * 1997-08-01 2004-02-24 The Johns Hopkins University School Of Medicine Methods to identify growth differentiation factor (GDF) binding proteins
AU8666398A (en) 1997-08-01 1999-02-22 Johns Hopkins University School Of Medicine, The Methods to identify growth differentiation factor (gdf) receptors
US6891082B2 (en) * 1997-08-01 2005-05-10 The Johns Hopkins University School Of Medicine Transgenic non-human animals expressing a truncated activintype II receptor
US5885779A (en) 1997-09-09 1999-03-23 University Of British Columbia Repressed trans-activator system for characterization of protein-protein interactions
DE19800422A1 (de) 1998-01-08 1999-07-15 Bosch Gmbh Robert Bremsvorrichtung für Fahrzeuge
CA2319703C (en) 1998-02-05 2005-09-20 The Johns Hopkins University School Of Medicine Growth differentiation factor-8
US6369201B1 (en) * 1998-02-19 2002-04-09 Metamorphix International, Inc. Myostatin multimers
US6004937A (en) 1998-03-09 1999-12-21 Genetics Institute, Inc. Use of follistatin to modulate growth and differentiation factor 8 [GDF-8] and bone morphogenic protein 11 [BMP-11]
US6368597B1 (en) 1998-05-06 2002-04-09 Matamorphix, Inc. Methods of treating diabetes
WO2000043781A2 (en) * 1999-01-21 2000-07-27 Metamorphix, Inc. Growth differentiation factor inhibitors and uses therefor
CN1384757A (zh) * 1999-07-20 2002-12-11 法麦克萨有限公司 下调gdf－8活性的方法

Also Published As

Publication number Publication date
BRPI0112785B1 (pt) 2016-07-12
US20110239317A1 (en) 2011-09-29
WO2002009641A9 (en) 2003-03-20
MXPA03000786A (es) 2004-05-21
NZ523672A (en) 2006-02-24
JP2004504826A (ja) 2004-02-19
PL210158B1 (pl) 2011-12-30
PL365780A1 (en) 2005-01-10
EP2360259A2 (en) 2011-08-24
NZ542696A (en) 2008-02-29
WO2002009641A2 (en) 2002-02-07
IL153970A0 (en) 2003-07-31
US7393682B1 (en) 2008-07-01
IL153970A (en) 2012-08-30
EP2360259A3 (en) 2011-11-16
EP1303534A4 (en) 2004-09-01
CN1449409A (zh) 2003-10-15
BR0112785A (pt) 2003-07-01
AR030307A1 (es) 2003-08-20
ZA200300483B (en) 2004-02-19
WO2002009641A3 (en) 2002-05-10
CN101261277B (zh) 2014-03-12
CN100429225C (zh) 2008-10-29
US20090017522A1 (en) 2009-01-15
CA2416260A1 (en) 2002-02-07
US8323964B2 (en) 2012-12-04
AU8079901A (en) 2002-02-13
EP1303534A2 (en) 2003-04-23
CN101261277A (zh) 2008-09-10
AU2001280799B2 (en) 2006-06-08

Similar Documents

Publication Publication Date Title
JP5149478B2 (ja) プロミオスタチンペプチドおよびその使用法
JP5153985B2 (ja) 増殖分化因子受容体、そのアゴニスト、およびアンタゴニスト、ならびにそれらの使用方法
US8822411B2 (en) Truncated activin type II receptor and methods of use
AU2001282999A1 (en) Growth differentiation factor receptors, agonists and antagonists thereof, and methods of using same
AU2001280799A1 (en) Promyostatin peptides and methods of using same
AU2011244851A1 (en) Promyostatin peptides and methods of using same
US7566768B1 (en) Promyostatin peptides and methods of using same
AU2007200633B2 (en) Growth differentiation factor receptors, agonists and antagonists thereof, and methods of using same
AU2006209266A1 (en) Promyostatin peptides and methods of using same
HK1161297A (en) Promyostatin peptides and methods of using same
HK1160723A (en) Use of follistatin to increase muscle mass

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20040108

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20080725

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20080725

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20080725

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20110601

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20110831

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20110907

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20111201

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20120416

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20120713

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20120723

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20121015

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20121105

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20121130

R150 Certificate of patent or registration of utility model

Free format text: JAPANESE INTERMEDIATE CODE: R150

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20151207

Year of fee payment: 3

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

LAPS Cancellation because of no payment of annual fees